TEXAS MEDICAID VENDOR DRUG PROGRAM DRUG UTILIZATION REVIEW BOARD MEETING - RETROSPECTIVE DRUG USE PROPOSALS

Friday, January 22, 2021

http://www.txvendordrug.com/

REVISED CRITERIA: ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

- **Dosage**
  - *Adults*
    - Table 1:
      - Moexipril: decreased maximum recommended dose from 60 mg to 30 mg daily
      - Altace® (ramipril): clarified indication "myocardial infarction/ stroke prophylaxis in patients 55 years of age or older"
  - *Pediatrics*
    - Table 3:
      - Vasotec® (enalapril): decreased maximum recommended dose from 0.61 mg/ kg/ day to 0.58 mg/ kg/ day
- **References** - updated

REVISED CRITERIA: ANGIOTENSIN II RECEPTOR BLOCKERS

- **Dosage**
  - *Adults*
    - Table 1:
      - Eprosartan: increased maximum dose from 800 mg to 900 mg daily
    - Table 2:
      - Teveten HCT®: (eprosartan/ hydrochlorothiazide): added to combination therapies
      - Byvalson® (nebivolol/valsartan): removed from criteria set, discontinued in 2018
- **Duplicative Therapies**
  - Addition of "2017 ACC/ AHA/ HFSA Focused Update of the 2013 ACCF/ AHA Guideline for the Management of Heart Failure" warning about combined use of ACE inhibitors and ARBs
- **References** - updated

REVISED CRITERIA: PLATELET AGGREGATION INHIBITORS

- **Dosage**
  - *Adults*
    - Table 1:
      - Durlaza® (aspirin): expected market availability updated to the middle of 2021
      - Dipyridamole: increased maximum dose from 300 mg to 400 mg daily
      - Effient® (prasugrel): updated dose reduction indications to include patients 75 years of age or older
      - Brilinta® (ticagrelor): updated indicated from "ACS" to "reduce risk death, MI, and stroke in patients with ACS, history of MI, or acute ischemic stroke/ high risk transient ischemic attack
      - Brilinta® (ticagrelor): added indication "reduce risk of first MI or stroke in patients with CAD at high risk of events"
    - Table 2:
      - Aggrenox® (dipyridamole/ aspirin): clarified indication from "stroke prevention" to "secondary stroke prevention"

REVISED CRITERIA: PLATELET AGGREGATION INHIBITORS

- **Dosage**
  - *Pediatrics*
    - Removed references to intravenous therapies cangrelor, eptifibatide, and tirofiban
- **References** - updated

REVISED CRITERIA: PROTON PUMP INHIBITORS

- **Dosage**
  - *Adults*
    - Table 1:
      - Esomeprazole strontium: removed from criteria set, product discontinued
      - Prilosec® (omeprazole: addition of 20.6 mg dosage
    - Table 3:
      - Esomeprazole strontium: removed from criteria set, product discontinued
  - *Pediatrics*
    - Vimovo® (esomeprazole/ naproxen): clarified indication for patients 12 years of age and older
- **References** - updated

REVISED CRITERIA: SEDATIVE HYPNOTICS

- **Dosage**
  - *Adults*
    - Separated dosage tables based off class
      - Table 1: benzodiazepines
      - Table 2: barbiturates
      - Table 3: non-benzodiazepine, benzodiazepine receptor agonists
      - Table 4: melatonin receptor agonists
      - Table 5: orexin receptor antagonists
      - Table 6: miscellaneous nonbarbiturates

REVISED CRITERIA: SEDATIVE HYPNOTICS

- **Dosage**
  - *Adults*
    - Table 1: benzodiazepines
      - Restoril® (temazepam): increased maximum dose from 15 mg to 30 mg daily
      - Doral® (quazepam): new addition
    - Table 5: orexin receptor antagonists
      - Dayvigo® (lemborexant): new addition
- **Drug Interactions**
  - Addition of lemborexant drug interaction: CYP3A inducers
- **References** - updated

REVISED CRITERIA: SEROTONIN 5-HT1B/1D RECEPTOR AGONISTS

- **Dosage**
  - *Adults*
    - Table 1:
      - Sumavel® DosePro® (sumatriptan): removed from criteria set, product discontinued
      - Tosymra® (sumatriptan) intranasal spray: new addition
    - Table 2:
      - Treximet® (sumatriptan/ naproxen): 10 mg/ 60 mg dose removed from criteria set, product discontinued
    - Table 6:
      - Sumatriptan nasal spray: added maximum recommended frequency for sumatriptan intranasal spray

REVISED CRITERIA: SEROTONIN 5-HT1B/1D RECEPTOR AGONISTS

- **Dosage continued**
  - *Pediatrics*
    - Rizatriptan: clarified that rizatriptan is the only triptan agent approved for use in pediatric patients less than 12 years of age
- **References** - updated